Lambda Biologics will be exhibiting at Neuroscience 2026, the Society for Neuroscience’s annual meeting and the world’s largest gathering of brain scientists.
Gene Therapy Rescues Patient-Derived Retinal Organoids
FDA Modernization Act 3.0 is not an animal-testing ban. See what it would change for NAMs, nonclinical testing, organoids, and oncology programs.
Meet Lambda Biologics at IFSCC 2026 to explore how hair & skin organoid advancing the next generation of cosmetic and dermatological claims.
A practical framework with 3 levels of validation for evaluating patient-derived organoid models and their suitability for drug testing at Lambda Biologics.
FDA Modernization Act 3.0 is not an animal-testing ban. See what it would change for NAMs, nonclinical testing, organoids, and oncology programs.
Explore the causes, symptoms and prevention of viral hepatitis this World Hepatitis Day 2026, and how HCC organoid models advance liver cancer research.
ODC26 unites the global organoid and NAMs community in Seoul, Sept 17–18, 2026. See the program, Korea's policy push, and Lambda Biologics' co-host role.
Pulmonary and intestinal fibrosis share a common TGF-β-driven mechanism. Our lung and intestinal organoid models capture it for antifibrotic drug discovery.
Lambda Biologics organoid models provide a human-relevant platform for evaluating ADC efficacy, mechanism of action, tumor heterogeneity, and response variability across patient-derived cancer models.
Learn how retinal organoids are advancing inherited retinal disease modeling, drug discovery, developmental biology, and regenerative medicine.
CRC organoids were utilized to evaluate the efficacy of candidate drugs, demonstrating superior anticancer effects compared to conventional therapies.
